Executive Summary
No approved drug has established an aging or lifespan-extension indication in humans. The most credible prescription candidates are approved for defined diseases and are being repurposed around geroscience hypotheses, most prominently rapamycin or sirolimus, metformin, acarbose, SGLT2 inhibitors, GLP-1-based metabolic therapies, and senolytic regimens built around dasatinib plus non-drug flavonoids.
The evidence hierarchy is uneven. Rapamycin, acarbose, and canagliflozin have notable mouse lifespan signals, but human data remain short-duration, biomarker-oriented, disease-specific, or exploratory. Metformin has the broadest historical use and a major aging-focused trial concept, but recent reviews emphasize uncertainty rather than confirmation.
Non-approved compounds occupy a different risk category. NAD+ precursors, spermidine, urolithin A, alpha-ketoglutarate, fisetin, quercetin, and peptide products are generally being evaluated through supplements, early trials, or unapproved research-product channels, with evidence centered on biomarkers, tolerability, muscle or cognitive endpoints, and disease-specific pilot studies rather than survival.
OSK partial reprogramming is the most biologically provocative area, but it is also the area most prone to overstatement. The headline mouse data use remaining lifespan in very old animals, while current clinical translation is beginning in localized disease settings such as optic neuropathy rather than systemic longevity treatment.
Regulatory and evidentiary frame
The central regulatory fact is that aging is not currently a conventional drug indication for U.S. labeling, so commercial longevity practice largely operates through two routes: approved products used for their labeled disease indications or prescribed off label, and non-approved compounds marketed as supplements, research products, or wellness interventions. This creates a persistent evidentiary mismatch between the biological ambition of geroscience and the indication-specific structure of drug approval. 12
The practical implication is that a drug may reduce cardiovascular events, glycemia, weight, inflammation, or disease-specific symptoms without proving that it slows biological aging or extends human lifespan. For a professional audience, the relevant question is not whether a pathway is aging-associated, but whether the intervention has prospective, controlled human evidence on clinically meaningful aging-related outcomes. 34
This distinction is particularly important for 2026 because several approved products now have strong outcomes data in defined cardiometabolic populations, while the direct longevity inference remains unproven. Semaglutide is a clear example: SELECT supported cardiovascular risk reduction in adults with established cardiovascular disease and overweight or obesity without diabetes, and labeling now includes reduction of major adverse cardiovascular events in the indicated population, but this is not equivalent to an approved anti-aging indication. 56
Approved therapies used in longevity practice
The approved-drug segment is not homogeneous. Some products are being used because they target canonical aging pathways, such as mTOR, AMPK, glucose handling, cellular senescence, or cardiorenal risk; others are being pulled into longevity narratives because they modify major age-related disease risks. The strongest interpretation is that these are repurposing candidates, not validated longevity treatments. 78
| Approved treatment or class | Labeled medical use | Longevity rationale | Current evidentiary boundary |
|---|---|---|---|
| Sirolimus, also known as rapamycin | Rapamune is indicated for prophylaxis of organ rejection in renal transplantation, with label warnings around immunosuppression, infection, lymphoma, malignancy, and transplant-specific risks. | mTOR inhibition is one of the most reproducible geroscience targets in animal models, and intermittent low-dose regimens are being evaluated in healthy aging adults. | The PEARL trial reported 48-week low-dose intermittent rapamycin experience in normative-aging adults, but available human evidence remains safety and healthspan-metric oriented rather than proof of lifespan extension. |
| Metformin | Metformin products are indicated as adjuncts to diet and exercise to improve glycemic control in type 2 diabetes. | Metformin is used in longevity practice because of AMPK, insulin-sensitization, observational disease-risk hypotheses, and the TAME concept for delaying age-related chronic diseases. | Recent reviews describe increasing uncertainty around metformin as an anti-aging intervention, and the TAME framework is designed to test composite age-related disease outcomes rather than a simple lifespan claim. |
| Acarbose | Acarbose is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. | Acarbose blunts post-prandial glucose excursions and has robust ITP mouse lifespan data, with larger median lifespan effects in males than females. | Human longevity data are not established; the mouse evidence is biologically interesting but does not define a clinical anti-aging indication. |
| SGLT2 inhibitors, illustrated by canagliflozin | Canagliflozin is approved for glycemic control in type 2 diabetes and for specified cardiovascular and kidney-risk reductions in defined diabetic populations. | SGLT2 inhibitors are attractive because of cardiorenal outcome benefits and canagliflozin ITP data in genetically heterogeneous mice. | Canagliflozin extended median survival in male but not female mice, and approved human benefits are disease and risk-population specific rather than aging-label claims. |
| GLP-1-based metabolic therapies, illustrated by semaglutide and tirzepatide | Semaglutide 2.4 mg and tirzepatide have obesity or weight-management indications, and semaglutide has a cardiovascular risk-reduction indication in adults with established cardiovascular disease and overweight or obesity. | The longevity narrative is driven by weight reduction, cardiometabolic risk modification, inflammation hypotheses, and mortality analyses in high-risk populations. | SELECT supports cardiovascular event reduction in a defined population, but GLP-1 therapy should be interpreted as disease-risk modification unless trials directly support aging or healthspan endpoints. |
| Dasatinib-based senolytic regimens | Dasatinib is approved for Philadelphia chromosome-positive chronic myeloid leukemia and acute lymphoblastic leukemia settings; quercetin is not a prescription drug in this combination. | Dasatinib plus quercetin is used as a senolytic strategy intended to clear senescent cells. | Early human studies in idiopathic pulmonary fibrosis and diabetic kidney disease are pilot or disease-specific and do not establish longevity efficacy in otherwise healthy adults. |
Interpretation by approved-drug category
Rapamycin remains the most visible pharmacologic longevity candidate because animal evidence is strong and mechanistically coherent, but the human translation remains incomplete. The PEARL study provides useful safety and healthspan-signal data over 48 weeks, while the sirolimus label underscores why casual translation is hazardous: the approved drug is an immunosuppressant with labeled infection and malignancy-related warnings in its transplant context. 910
Metformin has a different profile: large clinical familiarity, low cost, and a plausible geroscience rationale, but no definitive human anti-aging outcome. TAME is designed to evaluate whether metformin can delay development or progression of age-related chronic diseases in older adults, while recent critical reviews emphasize that the anti-aging case is less settled than early observational narratives suggested. 11124
Acarbose and canagliflozin are best understood as metabolism-linked signals from the Interventions Testing Program rather than as near-term human longevity products. Acarbose increased median longevity in HET3 mice with larger effects in males than females, and canagliflozin extended median survival in genetically heterogeneous male mice but not female mice; neither pattern can be assumed to translate into an unselected human longevity benefit. 71314
GLP-1-based therapies (Explore the GLP-1 Target Network) are the strongest example of a benefit that may be clinically important without being proof of aging modification. Semaglutide 2.4 mg reduced major adverse cardiovascular events in SELECT and is labeled for cardiovascular risk reduction in adults with established cardiovascular disease and overweight or obesity, but the appropriate conclusion is that reducing major disease risk can improve expected health outcomes in eligible patients, not that the drug has shown generalized lifespan extension. 5615
Dasatinib plus quercetin illustrates the translational tension in senolytics. The rationale is compelling because cellular senescence is implicated in age-related disease biology, but available human experience remains early, small, and disease-specific, including IPF feasibility work and diabetic kidney disease biomarker studies. For healthy adults, this remains an investigational extrapolation rather than an evidence-based longevity regimen. 161718
Non-approved compounds and supplement-adjacent interventions
The non-approved segment is broader and less disciplined than the prescription segment. It includes compounds sold as dietary supplements, naturally occurring metabolites, senolytic flavonoids, mitochondrial-function products, NAD+ boosters, and injectable peptides or research chemicals. Some have plausible biology and early human data; the common limitation is that biomarker movement is often being treated as if it were evidence of lifespan extension. 192021
| Non-approved compound or category | Longevity rationale | Human evidence signal | Boundary for 2026 interpretation |
|---|---|---|---|
| NAD+ precursors, including nicotinamide riboside and nicotinamide mononucleotide | Intended to raise NAD+ availability and support mitochondrial, DNA-repair, and metabolic pathways associated with aging biology. | Reviews and trials report NAD-related biomarker changes and short-term tolerability signals, with some small studies evaluating physical or metabolic endpoints. | Increased NAD+ metabolites should not be interpreted as proof of slower aging or longer life, and disease or function claims require endpoint-specific evidence. |
| Urolithin A | Positioned as a mitophagy and mitochondrial-health intervention. | Randomized trials in older or middle-aged adults reported tolerability and effects on muscle endurance, exercise performance, or mitochondrial biomarkers. | The current evidence supports investigation of muscle and mitochondrial endpoints, not a human lifespan-extension claim. |
| Spermidine | Autophagy-linked polyamine promoted for cognition and healthy aging. | A randomized trial in older adults with subjective cognitive decline did not modify memory and biomarkers compared with placebo, although exploratory signals were described. | The most conservative reading is that cognition and biomarker effects remain unconfirmed and dose, population, and endpoint selection are unresolved. |
| Fisetin and quercetin | Flavonoids used in senolytic narratives, often with fisetin alone or quercetin with dasatinib. | Fisetin trials are listed in older adults or chronic-disease populations, and quercetin appears in early senolytic studies with dasatinib. | Senolytic use in healthy adults remains investigational, and senescent-cell targeting can plausibly have context-dependent risks as well as benefits. |
| Alpha-ketoglutarate or calcium alpha-ketoglutarate | TCA-cycle metabolite promoted around metabolism, epigenetic clocks, and biological-age readouts. | Human evidence remains limited, with few studies and substantial reliance on biological-age or biomarker endpoints. | Clock movement is hypothesis-generating unless tied to prospective, clinically meaningful functional or disease outcomes. |
| Injectable peptides and research chemicals | Marketed around repair, body composition, recovery, or anti-aging narratives. | FDA has warned that unapproved versions of GLP-1 drugs and other online peptide products do not undergo FDA review for safety, effectiveness, and quality before marketing. | These products present a distinct regulatory and quality-risk category and should not be treated as equivalent to approved prescription products. |
OSK partial reprogramming: strong biology, narrow translation
OSK partial reprogramming refers to controlled expression of OCT4, SOX2, and KLF4, omitting c-MYC from the classic Yamanaka-factor set in many experimental systems to reduce reprogramming-associated oncogenic and dedifferentiation concerns. The field is important because it attempts to reset aspects of epigenetic aging while preserving cellular identity, but the same biology that makes the approach powerful also makes dose, tissue targeting, duration, and reversibility central safety variables. 2223
The most cited mouse lifespan result should be read carefully. In a 2024 study, systemic AAV-mediated inducible OSK delivery in 124-week-old male mice was reported to increase median remaining lifespan by 109%, but the underlying comparison was approximately 8.86 weeks of remaining life in controls versus 18.5 weeks in treated mice, with total median lifespan around 133 weeks versus 142.5 weeks. This is biologically meaningful in very old mice, but it is not the same as doubling full lifespan. 24
The magnitude issue matters because longevity communications often convert relative remaining-life effects into intuitive human-lifespan claims. A proportional increase in remaining life at extreme old age can be impressive while still corresponding to a much smaller absolute shift in total lifespan. That distinction is essential for avoiding unsupported conclusions about what OSK would do in humans. 2422
Other OSK data are supportive but not uniformly expansive. Long-term partial reprogramming in physiologically aged mice has been reported to alter age-associated molecular changes and produce rejuvenating effects in tissues such as kidney and skin, while neuron-specific OSK expression in a C. elegans model did not meaningfully ameliorate cognitive aging or extend lifespan and could disrupt behavior. These findings argue for tissue-specific development rather than a generalized assumption that OSK improves every aging phenotype. 2325
The clinical translation path also remains narrower than consumer longevity discourse suggests. Life Biosciences reported FDA clearance of an IND for ER-100 in January 2026 and described a Phase I program for optic neuropathies, including open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy. That is a localized disease-development program, not an approved systemic rejuvenation or longevity therapy. 2627
What would change the conclusion
The evidence threshold for a credible longevity claim should be higher than pathway plausibility. For approved drugs, the decisive data would be randomized, prospectively designed trials in relevant older populations with prespecified functional, multimorbidity, frailty, hospitalization, or mortality endpoints. For non-approved compounds, the first requirement is usually more basic: standardized product quality, dose-finding, safety characterization, and replication of clinically meaningful endpoint effects. 32
Biomarkers can be useful in trial design, but they are not substitutes for clinical benefit unless they are validated for the endpoint and context being claimed. This is especially important for epigenetic clocks, NAD+ metabolite levels, inflammatory markers, frailty indices, and tissue-specific molecular signatures, which may move in favorable directions without proving that a patient will live longer or avoid age-related disease. 1319
For OSK and other cellular-reprogramming modalities, the decisive questions are not only efficacy but also control. A clinically credible program will need to show tissue targeting, reversibility, avoidance of dedifferentiation or tumorigenic risk, durability of benefit, and clinically relevant functional improvement in the disease setting being treated. The first human programs are therefore more likely to proceed through localized age-related diseases than through systemic anti-aging claims. 222627
Conclusion
The most defensible 2026 position is that longevity pharmacology has become scientifically serious but commercially over-interpreted. Approved drugs such as sirolimus, metformin, acarbose, SGLT2 inhibitors, GLP-1-based therapies, and dasatinib provide credible starting points for geroscience because they act on pathways or diseases linked to aging, but their approved uses and human data do not establish generalized lifespan extension.
The non-approved compound space should be read as an early translational ecosystem rather than a validated anti-aging armamentarium. NAD+ precursors, urolithin A, spermidine, fisetin, quercetin, alpha-ketoglutarate, and peptides may generate useful research signals, but most current claims rest on biomarkers, small trials, or disease-specific endpoints. The gap between these signals and clinical longevity remains substantial.
OSK partial reprogramming clarifies the broader lesson. It may become one of the most important therapeutic ideas in aging biology, yet the strongest mouse lifespan findings depend on a relative remaining-life calculation in very old animals, and the first human development path is localized disease treatment. The correct conclusion is not dismissal, but disciplined skepticism: treat the biology as promising, the translation as early, and consumer-level longevity conclusions as unsupported until prospective human outcome data exist.